Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008;4(2):279-87.
doi: 10.2147/vhrm.s2132.

Management of venous thromboembolism in patients with cancer: role of dalteparin

Lori-Ann Linkins  1
Affiliations
Review

Management of venous thromboembolism in patients with cancer: role of dalteparin

Lori-Ann Linkins. Vasc Health Risk Manag. 2008.

Abstract

Cancer is a major risk factor for the development of venous thromboembolism (VTE). Conventional anticoagulant therapy with a vitamin K antagonist is more problematic in cancer patients due to an increased risk of recurrent VTE, and an increased risk of anticoagulant-related bleeding. In recent years, there has been a shift toward treating cancer patients with VTE with extended duration dalteparin. Dalteparin, a low-molecular-weight heparin, has been shown to be more effective, and as safe as conventional anticoagulant therapy, in cancer patients with VTE. This paper will (a) review the relationship between cancer and VTE, and (b) provide an overview of the role of dalteparin in the management of VTE in patients with cancer.

PubMed Disclaimer

Conflict of interest statement

Disclosures The author has no conflicts of interest to disclose.

Similar articles

See all similar articles

Cited by

References

    1. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, et al. Fragmin-Study Group. Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Thromb Haemost. 1994;71:698–702. - PubMed
    1. Anonymous. Fragmin (dalteparin sodium) Product Monograph. 2006
    1. Aujesky D, Smith KJ, Cornuz J, et al. Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism. Thromb Haemost. 2005;93:592–99. - PubMed
    1. Bergqvist D. Risk of venous thromboembolism in patients undergoing cancer surgery and options for thromboprophylaxis. J Surg Oncol. 2007;95:167–74. - PubMed
    1. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346:975–80. - PubMed